Verastem Receives Consensus Recommendation of “Buy” from Analysts (NASDAQ:VSTM)
Shares of Verastem (NASDAQ:VSTM) have been given a consensus rating of “Buy” by the eight ratings firms that are presently covering the stock, American Banking and Market News reports. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $19.50.
Shares of Verastem (NASDAQ:VSTM) traded down 9.23% during mid-day trading on Tuesday, hitting $8.16. The stock had a trading volume of 148,381 shares. Verastem has a 52 week low of $7.10 and a 52 week high of $18.82. The stock has a 50-day moving average of $9.34 and a 200-day moving average of $11.12. The company’s market cap is $210.8 million.
Verastem (NASDAQ:VSTM) last released its earnings data on Thursday, May 8th. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.43) by $0.08. On average, analysts predict that Verastem will post $-2.06 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on VSTM shares. Analysts at Oppenheimer initiated coverage on shares of Verastem in a research note on Monday. They set a “market perform” rating and a $8.99 price target on the stock. Analysts at Deutsche Bank initiated coverage on shares of Verastem in a research note on Tuesday, May 6th. They set a “buy” rating and a $14.00 price target on the stock.
Verastem, Inc is a United States-based biopharmaceutical company. The Company focuses on discovering and developing drugs to treat cancer by targeting cancer stem cells, which are an underlying cause of tumor recurrence and metastasis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.